Community-Led COVID-19 Testing Intervention to Address Mistrust

NCT07166770 | Completed

• 1 other identifier: 22-10-FB-0215 - Study 2
• Study Type: interventional
• Target: 49
• Locations: 1 country
• Sites: 1

Brief Summary

The goal of this adapted intervention study is to assess how community-led group discussions about health-related topics may alter beliefs and intentions regarding healthcare recommendations, such as COVID-19 testing and vaccination.

Conditions

COVID-19; Trust

Keywords

community-led; COVID-19; trust; vaccine hesitancy; peer mentor; community advisory board

Outcome Measures

Primary Outcomes (4)

• Openness to COVID-19 Testing

  The COVID-19 Testing Openness Questionnaire is an 7-item self-report measure designed to assess participants' openness to getting tested for COVID-19. Each item is rated on a 5-point scale, from 1 "Strongly Disagree" to 5 "Strongly Agree," with the sum of scores ranging from 7 to 35. Higher scores indicate greater openness to COVID-19 testing.

  0 weeks, 14 weeks, 18 weeks

• COVID-19 Testing Efficacy

  The COVID-19 Testing Efficacy Scale is a 6-item self-report measure that will assess participants' perceived self- and response-efficacy related to COVID-19 testing. Each item is rated on a 5-point scale ranging from 1 "Strongly Disagree" to 5 "Strongly Agree," with the sum of scores ranging between 6 and 30. Higher scores indicate greater efficacy.

  0 weeks, 14 weeks, 18 weeks

• Trust in the Safety of the COVID-19 Vaccine

  Trust in the safety of the COVID-19 vaccine was measured with one item which assessed participants' trust in the safety of the COVID-19 vaccine. The item is rated on a 5-point Likert scale. Higher scores indicate greater trust.

  0 weeks, 14 weeks, 18 weeks

• Trust in Efficacy of the COVID-19 Vaccine

  Trust in the efficacy of the COVID-19 vaccine was measured with one item which assessed participants' perceptions of efficacy related to the COVID-19 vaccine, or trust that it works as intended. The item is rated on a 5-point Likert scale. Higher scores indicate greater trust.

  0 weeks, 14 weeks, 18 weeks

Secondary Outcomes (3)

• COVID-19 Vaccine Hesitancy

  0 weeks, 14 weeks, 18 weeks

• Social Connectedness

  0 weeks, 14 weeks, 18 weeks

• Health Literacy

  0 weeks, 14 weeks, 18 weeks

Study Arms (2)

Control

NO INTERVENTION

non-intervention control (participants complete surveys only)

Intervention

EXPERIMENTAL

Participants engage in weekly community-led small group discussions about health-related topics and answer surveys at 0, 14, and 18 week time points

Behavioral: Community-led discussion

Interventions

Community-led discussion BEHAVIORAL

Participants engage in weekly community-led small group discussions about health related topics

Intervention

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• years or older
• Resident of one of the 9 housing authority agencies
• Willing to participate in Zoom meetings and complete online assessments at baseline, 14-week, and 18-week timepoints
• Ability to read, speak, and understand English

You may not qualify if:

• May not have participated in Study 1

Sponsors & Collaborators

• Old Dominion University: lead

Study Sites (1)

Macon & Joan Brock Virginia Health Institute at Old Dominion University

Norfolk, Virginia, 23507, United States

Location

MeSH Terms

Conditions

COVID-19; Vaccination Hesitancy

Condition Hierarchy (Ancestors)

Pneumonia, Viral; Pneumonia; Respiratory Tract Infections; Infections; Virus Diseases; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Lung Diseases; Respiratory Tract Diseases; Vaccination Refusal; Treatment Refusal; Treatment Adherence and Compliance; Health Behavior; Behavior

Study Officials

• Kelli J England, PhD

  Old Dominion University

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: PREVENTION
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor

Model Details: Participants randomly assigned to intervention or control group; repeated measure assessments at 0 weeks, 14 weeks, and 18 weeks

Study Record Dates

• First Submitted: September 5, 2025
• First Posted: September 10, 2025
• Study Start: July 1, 2025
• Primary Completion: January 27, 2026
• Study Completion: January 27, 2026
• Last Updated: September 11, 2026

Record last verified: 2026-09

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)